ClinVar Miner

Submissions for variant NM_001083962.2(TCF4):c.637_639delinsCTTCATGCAACCAGCACTT (p.Ser213fs)

dbSNP: rs2062114611
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Clinical Genomics Laboratory, Stanford Medicine RCV001253783 SCV001427086 pathogenic Pitt-Hopkins syndrome 2019-10-04 no assertion criteria provided clinical testing The p.Ser213Leufs*18 variant in the TCF4 gene was identified de novo in this individual and has not been previously reported in association with disease. This variant was absent from large population databases, including the Genome Aggregation Database (http://gnomad.broadinstitute.org/). The p.Ser213Leufs*18 variant results in a 3 bp deletion and 19 bp insertion, which causes a shift in the protein reading frame, leading to a premature termination codon 18 amino acids downstream. Heterozygous loss of function is an established mechanism of disease for the TCF4 gene (Zweier et al., 2008; Whalen et al., 2012; Sweetser et al., 2012). These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, there is sufficient evidence to classify the p.Ser213Leufs*18 variant as pathogenic for autosomal dominant Pitt-Hopkins syndrome based on the information above. [ACMG evidence codes used: PVS1; PS2; PM2]

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.